Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The benzodiazepine-type receptor refers to specific allosteric binding sites located on the GABAA receptor complex in the central nervous system. These sites are the molecular targets for benzodiazepine drugs, which are widely used for their anxiolytic, sedative, muscle relaxant, and anticonvulsant properties. Benzodiazepines act as positive allosteric modulators, enhancing the effect of the endogenous ligand GABA by increasing the affinity of the GABA binding site. This leads to increased chloride ion influx, hyperpolarization of neurons, and increased inhibitory neurotransmission.
Positive allosteric modulation of the GABAA receptor
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Benzodiazepine-type Receptor.